Regulatory T cell therapy for type 1 diabetes: May the force be with you

Journal of Autoimmunity

Volumn 71, Issue , 2016, Pages 78-87

  Gitelman, Stephen E ^a   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Regulatory T cells; Type 1 diabetes mellitus

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; T LYMPHOCYTE RECEPTOR;

CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL THERAPY; EX VIVO STUDY; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT DURATION; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANIMAL; AUTOIMMUNITY; BIOLOGICAL THERAPY; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNITY; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS, PHASE I AS TOPIC; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INSULIN-SECRETING CELLS; LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84964668143     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.03.011     Document Type: Review

References (85)

1. National Diabetes Statistics Report 2014, http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
2. Imperatore G., Boyle J.P., Thompson T.J., Case D., Dabelea D., Hamman R.F., et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012, 35(12):2515-2520.
3. Miller K.M., Foster N.C., Beck R.W., Bergenstal R.M., DuBose S.N., DiMeglio L.A., et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015, 38(6):971-978.
4. Steele C., Hagopian W.A., Gitelman S., Masharani U., Cavaghan M., Rother K.I., et al. Insulin secretion in type 1 diabetes. Diabetes 2004, 53(2):426-433.
5. Campbell-Thompson M., Fu A., Kaddis J.S., Wasserfall C., Schatz D.A., Pugliese A., et al. Insulitis and beta-cell mass in the natural history of type 1 diabetes. Diabetes 2016, 65(3):719-731.
6. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464(7293):1293-1300.
7. Cyclosporin-induced remission of IDDM after early intervention Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-european randomized control trial group. Diabetes 1988, 37(11):1574-1582.
8. Feutren G., Papoz L., Assan R., Vialettes B., Karsenty G., Vexiau P., et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2(8499):119-124.
9. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352(25):2598-2608.
10. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54(6):1763-1769.
11. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62(11):3766-3774.
12. Rigby M.R., Harris K.M., Pinckney A., DiMeglio L.A., Rendell M.S., Felner E.I., et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Investig. 2015, 125(8):3285-3296.
13. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378(9789):412-419.
14. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117(3):1061-1070.
15. Sakaguchi S., Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T. Regulatory T cells: how do they suppress immune responses?. Int. Immunol. 2009, 21(10):1105-1111.
16. Bluestone J.A., Bour-Jordan H., Cheng M., Anderson M. T cells in the control of organ-specific autoimmunity. J. Clin. Investig. 2015, 125(6):2250-2260.
17. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 2008, 9(3):239-244.
18. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11(1):7-13.
19. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27(1):20-21.
20. Xavier-da-Silva M.M., Moreira-Filho C.A., Suzuki E., Patricio F., Coutinho A., Carneiro-Sampaio M., Fetal-onset I.P.E.X. Report of two families and review of literature. Clin. Immunol. 2015, 156(2):131-140.
21. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11(12):1093-1101.
22. Munn D.H., Mellor A.L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013, 34(3):137-143.
23. Tang Q., Boden E.K., Henriksen K.J., Bour-Jordan H., Bi M., Bluestone J.A. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 2004, 34(11):2996-3005.
24. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(15):6335-6340.
25. Young A., Mittal D., Stagg J., Smyth M.J. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014, 4(8):879-888.
26. Heiber J.F., Geiger T.L. Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions. Cell Immunol. 2012, 279(1):60-65.
27. Alyanakian M.A., Grela F., Aumeunier A., Chiavaroli C., Gouarin C., Bardel E., et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006, 55(1):179-185.
28. Bettini M., Szymczak-Workman A.L., Forbes K., Castellaw A.H., Selby M., Pan X., et al. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J. Immunol. 2011, 187(7):3493-3498.
29. Green E.A., Gorelik L., McGregor C.M., Tran E.H., Flavell R.A. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(19):10878-10883.
30. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
31. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332(6029):600-603.
32. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001, 19:225-252.
33. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12(4):431-440.
34. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28(5):687-697.
35. Bettini M.L., Pan F., Bettini M., Finkelstein D., Rehg J.E., Floess S., et al. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 2012, 36(5):717-730.
36. D'Alise A.M., Ergun A., Hill J.A., Mathis D., Benoist C. A cluster of coregulated genes determines TGF-beta-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(21):8737-8742.
37. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54(1):92-99.
38. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54(5):1407-1414.
39. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59(2):407-415.
40. Dendrou C.A., Plagnol V., Fung E., Yang J.H., Downes K., Cooper J.D., et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 2009, 41(9):1011-1015.
41. Maier L.M., Lowe C.E., Cooper J., Downes K., Anderson D.E., Severson C., et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009, 5(1):e1000322.
42. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61(9):2340-2348.
43. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 2010, 207(9):1871-1878.
44. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., Masteller E.L., McDevitt H., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199(11):1455-1465.
45. Waldron-Lynch F., Henegariu O., Deng S., Preston-Hurlburt P., Tooley J., Flavell R., et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 2012, 4(118). 118ra112.
46. Daifotis A.G., Koenig S., Chatenoud L., Herold K.C. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin. Immunol. 2013, 149(3):268-278.
47. Penaranda C., Tang Q., Bluestone J.A. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 2011, 187(4):2015-2022.
48. Gitelman S.E., Gottlieb P.A., Rigby M.R., Felner E.I., Willi S.M., Fisher L.K., et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013, 1(4):306-316.
49. Haller M.J., Gitelman S.E., Gottlieb P.A., Michels A.W., Rosenthal S.M., Shuster J.J., et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J. Clin. Investig. 2015, 125(1):448-455.
50. Tooley J.E., Vudattu N., Choi J., Cotsapas C., Devine L., Raddassi K., et al. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur. J. Immunol. 2016, 46(1):230-241.
51. Putnam A.L., Brusko T.M., Lee M.R., Liu W., Szot G.L., Ghosh T., et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009, 58(3):652-662.
52. Bluestone J.A., Buckner J.H., Fitch M., Gitelman S.E., Gupta S., Hellerstein M.K., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 2015, 7(315). 315ra189.
53. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 2011, 186(7):3918-3926.
54. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10(9):1000-1007.
55. Bailey-Bucktrout S.L., Bluestone J.A. Regulatory T cells: stability revisited. Trends Immunol. 2011, 32(7):301-306.
56. Tang Q., Lee K. Regulatory T-cell therapy for transplantation: how many cells do we need?. Curr. Opin. Organ Transpl. 2012, 17(4):349-354.
57. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., Juscinska J., et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012, 35(9):1817-1820.
58. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Derkowska I., Juscinska J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 2014, 153(1):23-30.
59. Herold K.C., Usmani-Brown S., Ghazi T., Lebastchi J., Beam C.A., Bellin M.D., Ledizet M., et al. Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J. Clin. Investig. 2015, 125(3):1163-1173.
60. Thomas H.R., Gitelman S.E. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr. Diabetes 2013, 14(5):311-321.
61. Staeva T.P., Chatenoud L., Insel R., Atkinson M.A. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013, 62(1):9-17.
62. Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26:453-479.
63. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365(22):2055-2066.
64. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 2011, 365(22):2067-2077.
65. Castela E., Le Duff F., Butori C., Ticchioni M., Hofman P., Bahadoran P., et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014, 150(7):748-751.
66. Hartemann A., Bensimon G., Payan C.A., Jacqueminet S., Bourron O., Nicolas N., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1(4):295-305.
67. Rosenzwajg M., Churlaud G., Mallone R., Six A., Derian N., Chaara W., et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J. Autoimmun. 2015, 58:48-58.
68. Theil A., Wilhelm C., Guhr E., Reinhardt J., Bonifacio E. The relative merits of cord blood as a cell source for autologous T regulatory cell therapy in type 1 diabetes. Horm. Metab. Res. 2015, 47(1):48-55.
69. Brunstein C.G., Miller J.S., McKenna D.H., Hippen K.L., DeFor T.E., Sumstad D., et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect. Blood 2016, 127(8):1044-1051.
70. Haller M.J., Wasserfall C.H., Hulme M.A., Cintron M., Brusko T.M., McGrail K.M., et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care 2011, 34(12):2567-2569.
71. Giannopoulou E.Z., Puff R., Beyerlein A., von Luettichau I., Boerschmann H., Schatz D., et al. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial. Pediatr. Diabetes 2014, 15(2):100-109.
72. Roep B.O., Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2012, 2(4):a007781.
73. Wright G.P., Notley C.A., Xue S.A., Bendle G.M., Holler A., Schumacher T.N., et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(45):19078-19083.
74. Elinav E., Adam N., Waks T., Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009, 136(5):1721-1731.
75. Elinav E., Waks T., Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 2008, 134(7):2014-2024.
76. Fransson M., Piras E., Burman J., Nilsson B., Essand M., Lu B., et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflamm. 2012, 9:112.
77. Trzonkowski P., Bieniaszewska M., Juscinska J., Dobyszuk A., Krzystyniak A., Marek N., et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 2009, 133(1):22-26.
78. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117(14):3921-3928.
79. Edinger M., Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr. Opin. Immunol. 2011, 23(5):679-684.
80. Bacchetta R., Lucarelli B., Sartirana C., Gregori S., Lupo Stanghellini M.T., et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. Front. Immunol. 2014, 5:16.
81. Martelli M.F., Di Ianni M., Ruggeri L., Falzetti F., Carotti A., Terenzi A., et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014, 124(4):638-644.
82. Desreumaux P., Foussat A., Allez M., Beaugerie L., Hebuterne X., Bouhnik Y., et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012, 143(5). 1207-17 e1201-1202.
83. Canavan J.B., Scotta C., Vossenkamper A., Goldberg R., Elder M.J., Shoval I., et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut 2016, 65(4):584-594.
84. Gregoire S., Terrada C., Martin G.H., Fourcade G., Baeyens A., Marodon G., et al. Treatment of uveitis by in situ administration of ex vivo-activated polyclonal regulatory t cells. J. Immunol. 2016, 196(5):2109-2118.
85. Hutchinson J.A., Geissler E.K. Now or never? the case for cell-based immunosuppression in kidney transplantation. Kidney Int. 2015, 87(6):1116-1124.